PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
NYSE:PBH - New York Stock Exchange, Inc. - US74112D1019 - Common Stock - Currency: USD
Taking everything into account, PBH scores 6 out of 10 in our fundamental rating. PBH was compared to 193 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making PBH a very profitable company, without any liquidiy or solvency issues. PBH is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
PBH had positive earnings in the past year.
PBH had a positive operating cash flow in the past year.
PBH had positive earnings in 4 of the past 5 years.
PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of PBH (6.31%) is better than 90.67% of its industry peers.
Looking at the Return On Equity, with a value of 11.70%, PBH belongs to the top of the industry, outperforming 88.08% of the companies in the same industry.
The Return On Invested Capital of PBH (8.02%) is better than 85.49% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PBH is significantly below the industry average of 14.96%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.31% | ||
| ROE | 11.7% | ||
| ROIC | 8.02% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
Looking at the Profit Margin, with a value of 18.86%, PBH belongs to the top of the industry, outperforming 92.23% of the companies in the same industry.
In the last couple of years the Profit Margin of PBH has grown nicely.
PBH's Operating Margin of 30.70% is amongst the best of the industry. PBH outperforms 94.82% of its industry peers.
PBH's Operating Margin has been stable in the last couple of years.
PBH has a Gross Margin of 55.76%. This is in the better half of the industry: PBH outperforms 65.80% of its industry peers.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.7% | ||
| PM (TTM) | 18.86% | ||
| GM | 55.76% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PBH has been reduced compared to 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
PBH has a better debt/assets ratio than last year.
2.2 Solvency
PBH has an Altman-Z score of 2.83. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.83, PBH is in the better half of the industry, outperforming 70.98% of the companies in the same industry.
PBH has a debt to FCF ratio of 4.17. This is a neutral value as PBH would need 4.17 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.17, PBH belongs to the top of the industry, outperforming 86.01% of the companies in the same industry.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.55, PBH is doing worse than 62.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 4.17 | ||
| Altman-Z | 2.83 |
ROIC/WACC0.9
WACC8.87%
2.3 Liquidity
PBH has a Current Ratio of 4.20. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.20, PBH is doing good in the industry, outperforming 64.25% of the companies in the same industry.
PBH has a Quick Ratio of 2.82. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
PBH has a Quick ratio (2.82) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.82 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.63%, which is quite good.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
PBH shows a small growth in Revenue. In the last year, the Revenue has grown by 1.10%.
The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)8.63%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%34.69%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%7.05%
3.2 Future
Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 4.65% on average per year.
The Revenue is expected to grow by 2.00% on average over the next years.
EPS Next Y6.35%
EPS Next 2Y5.88%
EPS Next 3Y5.22%
EPS Next 5Y4.65%
Revenue Next Year1.66%
Revenue Next 2Y1.87%
Revenue Next 3Y1.95%
Revenue Next 5Y2%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.34 indicates a correct valuation of PBH.
Based on the Price/Earnings ratio, PBH is valued cheaply inside the industry as 84.46% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.03, PBH is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 15.37, the valuation of PBH can be described as correct.
Based on the Price/Forward Earnings ratio, PBH is valued a bit cheaper than 78.24% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.28. PBH is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.34 | ||
| Fwd PE | 15.37 |
4.2 Price Multiples
84.46% of the companies in the same industry are more expensive than PBH, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 86.53% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.98 | ||
| EV/EBITDA | 12.03 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.57
PEG (5Y)1.84
EPS Next 2Y5.88%
EPS Next 3Y5.22%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
74.04
-0.16 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.21%
Inst Owner Change0.11%
Ins Owners1.41%
Ins Owner Change4.43%
Market Cap3.64B
Analysts78
Price Target92.62 (25.09%)
Short Float %3.12%
Short Ratio4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.47%
Min EPS beat(2)0.64%
Max EPS beat(2)4.3%
EPS beat(4)3
Avg EPS beat(4)2.01%
Min EPS beat(4)-0.47%
Max EPS beat(4)4.3%
EPS beat(8)5
Avg EPS beat(8)-0.35%
EPS beat(12)8
Avg EPS beat(12)-46.35%
EPS beat(16)12
Avg EPS beat(16)-31.94%
Revenue beat(2)2
Avg Revenue beat(2)0.9%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.46%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)1.57%
Revenue beat(8)3
Avg Revenue beat(8)-0.39%
Revenue beat(12)6
Avg Revenue beat(12)0.09%
Revenue beat(16)10
Avg Revenue beat(16)1.7%
PT rev (1m)0%
PT rev (3m)2.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.34 | ||
| Fwd PE | 15.37 | ||
| P/S | 3.2 | ||
| P/FCF | 14.98 | ||
| P/OCF | 14.49 | ||
| P/B | 1.99 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.03 |
EPS(TTM)4.53
EY6.12%
EPS(NY)4.82
Fwd EY6.51%
FCF(TTM)4.94
FCFY6.67%
OCF(TTM)5.11
OCFY6.9%
SpS23.11
BVpS37.27
TBVpS-20.07
PEG (NY)2.57
PEG (5Y)1.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.31% | ||
| ROE | 11.7% | ||
| ROCE | 10.6% | ||
| ROIC | 8.02% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 70.49% | ||
| OM | 30.7% | ||
| PM (TTM) | 18.86% | ||
| GM | 55.76% | ||
| FCFM | 21.38% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexcg growth 3Y-14.1%
ROICexcg growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 4.17 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 27.26% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.31 | ||
| Cash Conversion | 66.29% | ||
| Profit Quality | 113.37% | ||
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.82 | ||
| Altman-Z | 2.83 |
F-Score7
WACC8.87%
ROIC/WACC0.9
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.63%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%34.69%
EPS Next Y6.35%
EPS Next 2Y5.88%
EPS Next 3Y5.22%
EPS Next 5Y4.65%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%7.05%
Revenue Next Year1.66%
Revenue Next 2Y1.87%
Revenue Next 3Y1.95%
Revenue Next 5Y2%
EBIT growth 1Y1.99%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year11.34%
EBIT Next 3Y4.95%
EBIT Next 5Y3.8%
FCF growth 1Y1.64%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y1.04%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%